Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs' CAR-T Therapy Development Services provide a comprehensive solution for overcoming the immunosuppressive tumor microenvironment (TME) and unlocking the full potential of immuno-oncology. Featuring advanced cell engineering, rational combination therapy design, and proprietary screening platforms, this service empowers the development of highly potent, TME-resistant CAR-T therapeutics. By integrating multi-dimensional optimization and mechanistic insight, it ensures enhanced efficacy and durability, offering researchers a strategic pathway to advance next-generation solid tumor immunotherapies.
CAR-T cell therapy has revolutionized hematologic cancer treatment, but the immunosuppressive TME severely limits efficacy against solid tumors. The TME erects physical barriers (e.g., the BBB, poor vascularization) and molecular defenses (e.g., checkpoint ligands, inhibitory cytokines) that induce CAR-T cell exhaustion and anergy. Creative Biolabs specializes in designing next-generation CAR-T cells that are genetically or pharmacologically armed to reprogram the TME, overcoming these obstacles to enhance T-cell infiltration, effector function, and persistence, ultimately driving clinical success in challenging indications.
Fig.1 Immune microenvironment of tumor cells.1
At Creative Biolabs, we move beyond conventional CAR-T design to tackle the primary clinical obstacle in solid tumors: the immunosuppressive TME. We provide a comprehensive suite of solutions to engineer CAR-T cells for superior infiltration, persistence, and cytotoxicity in hostile tumor environments. Our goal is to translate cutting-edge research, such as exploiting chemokine gradients or genetically arming T-cells, into a reliable, scalable therapeutic product.
Discover How We Can Help - Request a Consultation.
| Target Immunosuppressive Cell & Checkpoint Axis | Target Cytokine & Chemokine Milieu |
|
|
The required starting materials include target antigen information for CAR targeting, tumor model data with TME characterization, and CAR construct design details or preferences.
The final deliverables include an engineered CAR-T cell bank with full characterization, a comprehensive efficacy data report on TME resistance and tumor control, and a transferable manufacturing protocol.
Our focus is on overcoming immune suppression by targeting immunosuppressive cells. Through advanced cell engineering and combinatorial targeting, we help you enhance CAR-T cell persistence, restore immune activation, and achieve potent antitumor efficacy even within highly suppressive solid tumor microenvironments.
We focus on remodeling the cytokine and chemokine milieu within the tumor microenvironment. By engineering CAR-T cells to resist inhibitory cytokines, secrete proinflammatory factors, or modulate chemokine gradients, we enhance tumor infiltration, improve immune cell coordination.
Creative Biolabs develops immune checkpoint–targeting CAR-T strategies to overcome TME-mediated immunosuppression. By engineering CAR-T cells to block or modulate checkpoint pathways, we enhance T-cell activation, persistence, and antitumor efficacy in solid tumor environments.
Creative Biolabs provides CAR-T–derived exosome development services designed to modulate the tumor microenvironment. These engineered exosomes deliver immunostimulatory signals and therapeutic cargos, helping overcome immunosuppressive barriers and enhancing antitumor immune responses.
Is systemic toxicity a concern with cytokine-secreting CAR-Ts?
Safety is prioritized through localized or inducible cytokine secretion and built-in safety switches, enabling rapid CAR-T elimination if adverse effects arise, ensuring functional yet safe therapies.
What's the advantage of PD-1 knockout over the antibody combination?
PD-1 KO offers a permanent, intrinsic resistance to exhaustion without extra drugs, yielding longer persistence and stronger cytokine secretion than antibody-combined CAR-T in antigen-dense tumors.
Is systemic toxicity a concern with cytokine-secreting CAR-Ts?
Safety is prioritized through localized or inducible cytokine secretion and built-in safety switches, enabling rapid CAR-T elimination if adverse effects arise, ensuring functional yet safe therapies.
To fully leverage the potential of your TME-resistant CAR-T therapy, Creative Biolabs offers complementary services designed for a streamlined development pipeline.
Creative Biolabs offers CAR-T therapy development services designed to overcome antigen heterogeneity and escape. By leveraging multi-target CAR designs, dual-antigen strategies, and advanced screening platforms, we ensure robust, precise, and sustained tumor cell elimination for challenging solid tumor indications.
Creative Biolabs provides CAR-T therapy development services to overcome poor trafficking and physical barriers in solid tumors. Utilizing engineered CAR-T cells, biomaterial delivery platforms, and tumor-penetrating strategies, we enhance tumor infiltration, persistence, and antitumor efficacy for difficult-to-reach tumor sites.
Creative Biolabs offers CAR-T therapy development services to overcome hypoxia and metabolic stress in the tumor microenvironment. By engineering resilient CAR-T cells and optimizing metabolic pathways, we enhance cell survival, functionality, and sustained antitumor activity in hostile solid tumor conditions.
Creative Biolabs is your expert partner in overcoming the final hurdle for solid tumor CAR-T therapy. Our Solid Tumor Targeting Creative Biolabs is your expert partner in developing next-generation CAR-T therapeutics engineered to conquer the immunosuppressive TME. Our scientific rigor, integrated safety mechanisms, and multi-modal engineering strategies ensure your project moves swiftly and confidently toward clinical success in solid tumor indications. Contact Our Team for More Information and to Discuss Your Project.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
